Sold as Fludeoxyglucose F18. Every FDA application for this active ingredient: 3 branded and 41 generic.
As of Nov 15, 2026, FDA lists 44 applications for Fludeoxyglucose F-18 (sold as Fludeoxyglucose F18), first approved Aug 19, 1994, with 1 new use approved and 0 published complete response letters.
| PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer ImagingProstate Cancer · The First Affiliated Hospital of Soochow University | Early phase 1 | Active, not recruiting | Nov 12, 2026 |
| Artificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic Cancer LesionsPancreas Carcinoma, PDAC - Pancreatic Ductal Adenocarcinoma · Ruijin Hospital | — | Recruiting | Nov 9, 2026 |
| Whole-Body ⁶⁸Ga-FAPI PET/CT in Cavernous Sinus Syndrome: A Prospective Comparison With ¹⁸F-FDG PET/CTCavernous Sinus Syndrome · Post Graduate Institute of Medical Education and Research, Chandigarh | — | Active, not recruiting | Nov 5, 2026 |
| PET/CT-Guided Maintenance Therapy in Previously Untreated MZLMarginal Zone Lymphoma(MZL) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Active, not recruiting | Nov 4, 2026 |
| Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate CancerMetastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 · National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Nov 4, 2026 |
| 18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal TumorsRenal Cell Carcinoma (RCC), Renal Pelvic Urothelial Carcinoma · Peking University First Hospital | Not applicable | Recruiting | Oct 15, 2026 |
| 68Ga- and 18F-CAIX PET Imaging StudyRenal Cell Carcinoma, Clear Cell Renal Cell Carcinoma · Peking University First Hospital | Early phase 1 | Not yet recruiting | Oct 15, 2026 |
| MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast CancerBreast Cancer, Neoadjuvant Therapy · Fudan University | Not applicable | Active, not recruiting | Oct 15, 2026 |
| Aug 19, 1994 | Fludeoxyglucose F18NDA 20306 · New molecular entity | Downstate Clincl | 7 | Discontinued |
| Aug 5, 2004 | Fludeoxyglucose F18NDA 21768 · New dosage form | Weill Medcl Coll | 1 | Discontinued |
| Aug 19, 2005 | Fludeoxyglucose F18NDA 21870 · New formulation or manufacturer | Feinstein | 11 | Marketed |
| Feb 25, 2011 | Fludeoxyglucose F18ANDA 79086 | Petnet | 3 | Marketed |
| Feb 14, 2013 | Fludeoxyglucose F18ANDA 203665 | Sofie | 0 | Discontinued |
| Jun 27, 2013 | Fludeoxyglucose F18ANDA 203811 | Ucla Biomedical | 0 | Marketed |
| Aug 5, 2013 | Fludeoxyglucose F18ANDA 203612 | Mcprf | 0 | Marketed |
| Dec 23, 2013 | Fludeoxyglucose F18ANDA 203709 | Wisconsin | 1 | Discontinued |
| Jan 13, 2014 | Fludeoxyglucose F18ANDA 203246 | Univ Tx Md Anderson | 1 | Marketed |
| Feb 4, 2014 | Fludeoxyglucose F18ANDA 203664 | Pharmalogic Hldgs | 0 | Marketed |
| Feb 5, 2014 | Fludeoxyglucose F18ANDA 203935 | Wusm Cyclotron | 1 | Marketed |
| Feb 5, 2014 | Fludeoxyglucose F18ANDA 203946 | Essential Isotopes | 1 | Discontinued |
| May 9, 2014 | Fludeoxyglucose F18ANDA 203902 | Ucsf Rodiopharm | 1 | Marketed |
| Aug 6, 2014 | Fludeoxyglucose F18ANDA 203990 | Uihc Pet Imaging | 0 | Marketed |
| Sep 25, 2014 | Fludeoxyglucose F18ANDA 204333 | Ma General Hosp | 2 | Marketed |
| Oct 21, 2014 | Fludeoxyglucose F18ANDA 204463 | Sofie | 1 | Marketed |
| Oct 29, 2014 | Fludeoxyglucose F18ANDA 203801 | Trustees Univ Pa | 0 | Marketed |
| Oct 29, 2014 | Fludeoxyglucose F18ANDA 204385 | Barbara Ann Karmanos | 1 | Marketed |
| Oct 29, 2014 | Fludeoxyglucose F18ANDA 204525 | Isologic Innovative | 1 | Marketed |
| Oct 30, 2014 | Fludeoxyglucose F18ANDA 203816 | Brigham Womens | 1 | Marketed |
| Oct 30, 2014 | Fludeoxyglucose F18ANDA 203937 | Hot Shots Nm LLC | 0 | Discontinued |
| Dec 18, 2014 | Fludeoxyglucose F18ANDA 204264 | Pharmalogic | 1 | Discontinued |
| Jan 7, 2015 | Fludeoxyglucose F18ANDA 204512 | Ncm USA Bronx LLC | 0 | Marketed |
| Feb 4, 2015 | Fludeoxyglucose F18ANDA 203994 | Northland | 0 | Marketed |
| Apr 7, 2015 | Fludeoxyglucose F18ANDA 204546 | Precision Nuclear | 0 | Marketed |
| Apr 22, 2015 | Fludeoxyglucose F18ANDA 203911 | Nukemed | 0 | Discontinued |
| Apr 23, 2015 | Fludeoxyglucose F18ANDA 203904 | Methodist Hosp Res | 0 | Marketed |
| May 1, 2015 | Fludeoxyglucose F18ANDA 203710 | Biomedcl Res Fdn | 1 | Marketed |
| May 1, 2015 | Fludeoxyglucose F18ANDA 203837 | Biomedcl Res Fdn | 1 | Marketed |
| Jun 23, 2015 | Fludeoxyglucose F18ANDA 203920 | Jubilant Draximage | 1 | Marketed |
| Jun 23, 2015 | Fludeoxyglucose F18ANDA 204498 | Univ Utah Cyclotron | 1 | Marketed |
| Jul 17, 2015 | Fludeoxyglucose F18ANDA 204531 | Univ Michigan | 0 | Marketed |
| Aug 31, 2015 | Fludeoxyglucose F18ANDA 203591 | Sofie | 1 | Marketed |
| Aug 31, 2015 | Fludeoxyglucose F18ANDA 203771 | Queen Hamamatsu Pet | 0 | Marketed |
| Sep 11, 2015 | Fludeoxyglucose F18ANDA 204472 | Mips Crf | 0 | Marketed |
| Oct 27, 2015 | Fludeoxyglucose F18ANDA 204759 | Kettering Medctr | 0 | Marketed |
| Oct 30, 2015 | Fludeoxyglucose F18ANDA 203778 | 3d Imaging Drug | 1 | Marketed |
| Nov 13, 2015 | Fludeoxyglucose F18ANDA 203603 | Cardinal Health 414 | 1 | Marketed |
| Nov 19, 2015 | Fludeoxyglucose F18ANDA 203736 | Midwest Medcl | 0 | Discontinued |
| Apr 11, 2016 | Fludeoxyglucose F18ANDA 203942 | Kreitchman Pet Ctr | 0 | Marketed |
| Dec 8, 2016 | Fludeoxyglucose F18ANDA 208679 | Mem Sloan-Kettering | 0 | Discontinued |
| Feb 6, 2020 | Fludeoxyglucose F18ANDA 210265 | Univ Tx Sw Medctr | 0 | Discontinued |
| Dec 16, 2020 | Fludeoxyglucose F18ANDA 209341 | Univ Southern Ca | 0 | Marketed |
| Mar 11, 2025 | Fludeoxyglucose F18ANDA 216125 | Bamf | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA